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Program in EgyptAbstract Background: MDR-TB is regarded as a high-priority medical and public health issue, its
treatment is frequently associated with prolonged illness and disability. Second-line TB drugs have a
greater incidence of adverse reactions, which increases the morbidity as well as cost.
Objective: To assess adverse reactions of second-line TB drugs in patients treated for MDR-TB
in Egypt from 1st of July 2006 to 1st of January 2009.
Methods: A retrospective study included 138 patients enrolled into the MDR-TB department at
the Abbassia Chest Hospital during the study period. The patient was treated with 5 drugs accord-
ing to results of the drug susceptibility test as follows: Any drug of the 1st line if not resistant, One
of the injectable aminoglycosides (Kanamycin, Amikacin, Capreomycin or Streptomycin),
Quinolones (Oﬂoxacin), Ethionamide, Cycloserine, and PAS. During the course of treatment, the
patients were followed up by radiological and laboratory investigation and adverse reactions were
determined by clinical and or laboratory criteria. Severity of adverse reactions was graded accord-
ing to the National Tuberculosis Program.
Results: Majority of cases were cured (88.4%), one patient was lost to follow-up, 4 patients com-
pleted treatment and 7 patients died. There was a signiﬁcant weight gain beginning from the 3rd
month of treatment. There were statistically signiﬁcant elevations of SGPT beginning from the
6th month, there were signiﬁcant elevations of creatinine beginning from the 3rd month while thererculosis.
658 M.A.T. El-Din et al.were no signiﬁcant changes in serum Potassium levels. Gastrointestinal manifestations were the
most frequent adverse reaction, followed by PN, hypokalemia, IBS, Ototoxicity,
Hypothyroidism, Skin manifestations, Hepatotoxicity then by nephrotoxicity. Hyponatremia and
dizziness were the least adverse reactions, the majority of adverse reactions did not affect daily
activity of the patients. There was a signiﬁcant relation between smoking and peripheral neuropathy
while there were no signiﬁcant relation between smoking, DM and used antituberculosis drugs with
the other adverse reactions.
Conclusion: The most common type of resistance was acquired resistance, There was a relation
between both tobacco smoking and drug addiction, and MDR TB, The most common side effect of
anti TB drugs was GIT manifestations and the least complication was dizziness. Adverse reactions
did not negatively impact treatment outcome among individuals who were adherent to treatment.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Tuberculosis (TB) is a medical, social and economic disaster
of immense magnitude that occurrs all over the world [1].
The emergence of drug-resistant strains of Mycobacterium
is a common consequence of inadequate therapeutic practice
[2]. Strains of Mycobacterium tuberculosis that are resistant to
both isoniazid and rifampicin with or without resistance to
other drugs have been termed multidrug-resistant strains.
Isoniazid and rifampicin are keystone drugs in the manage-
ment of TB. While resistance to either isoniazid or rifampicin
may be managed with other ﬁrst-line drugs, multidrug-
resistant TB (MDR-TB) demands treatment with second-
line drugs that have limited sterilizing capacity, and are less
effective and more toxic [3,4]. The treatment of MDR-TB is
frequently associated with prolonged illness and disability.
Second-line TB drugs have a greater incidence of adverse
reactions, which increases the morbidity as well as cost [5].
Generally, these second-line agents must be administered
more frequently than ﬁrst-line agents, making compliance
with medications more difﬁcult. Many authorities have advo-
cated that MDR-TB be regarded as a high-priority medical
and public health issue and that these patients should be
referred upon diagnosis to a specialized center for system-
atized and aggressive medical therapy [6]. The treatment of
MDR-TB is a challenge which should be undertaken by expe-
rienced clinicians at centers equipped with reliable laboratory
service for mycobacterial culture and in vitro sensitivity test-
ing [1,4,7].
The aim of this study is to assess adverse reactions of
second- line TB drugs in patients treated for MDR-TB in
Egypt from 1st of July 2006 to 1st of January 2009.
Patients and methods
This was a retrospective study that included 138 patients
enrolled into the MDR-TB department at the Abbassia
Chest Hospital, Cairo, Egypt, between 1st July 2006 and 1st
January 2009.
Patients were included in this study if they had active tuber-
culosis as evidenced by positive sputum for AFB and/or posi-
tive culture forM. tuberculosis in previously treated patients or
new cases suspect to be MDR-TB, and had been documented
as MDR-TB by the drug susceptibility test for 1st lineanti-tuberculosis drugs done in the National Reference
Laboratory. There were no exclusion criteria.
All cases were subjected to the following: Medical history
with special attention to: whether primary or secondary resis-
tance, special habits of medical importance, co-morbid dis-
eases. clinical examination, initial laboratory investigation:
serum potassium on admission then monthly while receiving
an injectable agent, liver functions (SGPT), renal functions
(Serum creatinine), HIV testing, and pregnancy test (for mar-
ried women of childbearing age, and repeated if indicated).
The patient was treated with 5 drugs according to results of
the drug susceptibility test (DST) with dosage as follows: any
drug of the 1st line if not resistant, one of the injectable amino-
glycosides (kanamycin, amikacin, capreomycin or strepto-
mycin), quinolones (oﬂoxacin), ethionamide, cycloserine, and
Para amino-salicylic acid (PAS).
Follow up of patients
During the course of treatment, the patients were followed up
by radiological and laboratory investigations such as: Sputum
smear and culture; monthly until conversion then smear
monthly and culture quarterly, Drug susceptibility test
(DST) for patients who remains culture positive at the end
of the intensive phase or after 8 months of treatment, Chest
X-ray every 6 months or when indicated, Serum creatinine,
monthly while receiving injectable drugs, Serum potassium
monthly while receiving injectable drugs, Liver enzymes; peri-
odic monitoring (every1–3 months), Thyroid stimulating hor-
mone (TSH) every 6 months if receiving ethionamide or PAS
and monthly for signs and symptoms of hypothyroidism,
Audiometry, visual acuity and psychiatric disorders assess-
ment, Hematological changes and allergic reactions when
indicated.
Adverse reactions
Adverse reactions were determined by clinical and or labora-
tory criteria as follows: Ototoxicity: tinnitus, hearing loss con-
ﬁrmed by audiometry, presence of disequilibrium, Psychiatric
disorders: presence of depression, anxiety, nightmares or psy-
chotic symptoms, Gastrointestinal effects: nausea, vomiting,
abdominal pain, haematemesis, melena, diarrhea, positive
endoscopic ﬁndings. Arthralgia, arthritis: pain or swelling in
Table 1 Demographic and special habits of medical impor-
tance in the studied cases.
Mean ± SD Range
Age (years) 37.6 ± 12.3 15.0–67.0
N %
Sex
Male 99 71.7
Female 39 28.3
Smoking 38 27.5
Addiction 4 2.9
Alcohol 7 5.1
Co-morbidities N %
DM 48 34.8
Chronic liver diseases 5 3.6
Chronic renal diseases 1 0.7
Ischemic heart diseases 2 1.4
Chronic pulmonary diseases 4 2.9
HIV 1 0.7
No co-morbidity 77 55.9
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(CNS): seizure activity of any type as reported by the patient
or witnessed by another individual, Hepatitis: any elevation
of serum transaminases in the presence of symptoms or eleva-
tion of serum transaminases to ﬁve times the normal values
without any symptoms, Dermatologic: any skin change char-
acterizing rash or bronzing, Peripheral neuropathy: numbness,
weakness, tingling or burning in the extremities, peripheral
neuropathy conﬁrmed by electromyography, Nephrotoxicity:
rise in the serum creatinine of 0.5 mg/dl from the baseline at
any time during treatment, Hypothyroidism: any rise of serum
thyroid stimulating hormone (TSH) > 10 mU/L.
Severity of adverse reactions was graded according to
National Tuberculosis Program (NTP) as follows:
 Asymptomatic.
 Don’t affect daily activities.
 Limit daily activities.
 Life threatening condition [8]
Speciﬁc treatment for every adverse reaction; reduced
dosage of suspected drug(s); and removal of drug(s) from the
regimen.
Treatment outcome
Treatment outcome was deﬁned according to WHO, 2013 as
follows:
s Cured: Treatment completed as recommended by the
national policy without evidence of failure, and three or
more consecutive cultures taken >30 days apart are nega-
tive after the intensive phase.
s Treatment completed: Treatment completed as recom-
mended by the national policy without evidence of failure,
but no record that three or more consecutive cultures taken
>30 days apart are negative after the intensive phase.
s Treatment failed: Treatment terminated or need for perma-
nent regimen change of at least two anti-TB drugs because
of lack of conversion’’ by the end of the intensive phase, or
bacteriological reversion’’ in the continuation phase after
conversion to negative, or evidence of additional acquired
resistance to ﬂuoroquinolones, or adverse drug reactions.
s Died: A patient who dies for any reason during the course
of treatment.
s Lost to follow-up: A patient whose treatment was inter-
rupted for two consecutive months or more (this category
was previously known as ‘‘defaulted’’.
s Not evaluated: A patient for whom no treatment outcome
is assigned (this includes cases ‘‘transferred out’’ to another
treatment unit and whose treatment outcome is unknown
[9].
Data analysis
The collected data were statistically analyzed using IBM SPSS
statistics (Statistical Package for Social Sciences) (V. 22.0) soft-
ware version 22.0, IBM Corp., USA, 2013. Descriptive statis-
tics were done for quantitative data as minimum, maximum
and mean ± SD for quantitative parametric data, medianand 1st and 3rd inter-quartile range for quantitative non-
parametric data, while it was done for qualitative data as num-
ber and percentage. Inferential analyses were done for quanti-
tative variables using the paired t-test in cases of two
dependent groups with parametric data and Wilcoxon signed
rank test in cases of two dependent groups with non-
parametric data. In qualitative data, inferential analyses for
independent variables were done using the Chi square test
for differences between proportions. P value <0.05 is consid-
ered signiﬁcant.
Results
The study included 138 patients, the number of enrolled cases
in the study according to year of admission were 27 in 2006, 42
in 2007and 69 in 2008.
Patient characteristics regarding age, sex, special habits of
medical importance and comorbid diseases are shown in
Table 1.
Demographic, special habits of medical importance
(Tobacco smoking – Drug addiction – alcohol consumption)
and comorbid diseases of the studied patients. Data are pre-
sented either as mean ± SD or frequency (N) and percentage
(%).
DM was the most frequent co-morbidity, which affected
about one third of cases followed by chronic liver disease then
chronic pulmonary disease (COPD) while the majority of cases
in the studied group had no co-morbid diseases.
Regarding the type of resistance; 132 patients were sec-
ondary resistant ‘‘resistance in previously treated cases,’’ while
6 patients only were primarry resistant ‘‘resistance in new
cases’’.
As regards the 2nd line drugs taken by the patients; all of
them share one drug (Oﬂoxacin) and almost shared
Ethionamide (137), Cycloserine (136), PAS (137) but they were
different as regard to the injectable aminoglycosides.
Kanamycin was the most frequent injectable drug (73), fol-
lowed by amikacin (42) then Capreomycin (18) and
Streptomycin was the least one (5 patients). Also, two drugs
Table 3 Treatment outcome of the studied cases.
Outcome N %
Cured 122 88.4
Lost to follow-up 1 0.7
Treatment completed 4 2.9
Died 11 8.0
Treatment outcome of the studied cases described as frequency (N)
and percentage (%).
Figure 1 Weight among the studied cases. The difference from
each month to 1st month studied using paired t-test.
Figure 2 SGPT among the studied cases using Wilcoxon signed
rank test, difference from each month to 1st month. Elevations
were statistically signiﬁcant beginning from 6th month (p< 0.05).
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(3 patients only). This is presented in Table 2.
At the end of treatment the majority of cases were cured
after a full course of treatment (88.4%), while one patient
was lost to follow-up, 4 patients completed treatment and 7
patients died. Results are described in Table 3.
There was a signiﬁcant weight gain beginning from the 3rd
month of treatment as shown in Fig. 1.
Regarding laboratory follow up tests for the drug effects;
there were elevations of SGPT beginning from the 3rd month
after treatment, but the elevations were statistically signiﬁcant
beginning from the 6th month as illustrated in Fig. 2.
Also there were signiﬁcant elevations of creatinine begin-
ning from the 3rd month of treatment as presented in Fig. 3,
while there were no signiﬁcant changes in serum potassium
levels among the studied cases all through the follow up period
as shown in Fig. 4.
As regards the adverse effects of the used drugs; gastroin-
testinal manifestations were the most frequent adverse reac-
tion, followed by PN, hypokalemia, Ototoxicity,
Hypothyroidism, Skin manifestations, Hepatotoxicity then
nephrotoxicity. Hyponatremia and dizziness were the least
encountered adverse reactions. This is illustrated in Fig. 5.
The severities of adverse reactions according to NTP pro-
gram (presented in Table 4) were as follows:
(1) Does not affect daily activity
(2) Limits daily activity
(3) Life threatening conditions.
The majority of adverse reactions did not affect daily activ-
ity of the patients.
Comparisons between cases with and without adverse reac-
tions were done using the Chi square test as regards smoking
being the most special habit of medical importance in the stud-
ied group and other special habits (drug addiction and alcohol
consumption) were rare. In addition, comparisons were done
using the Chi square test between cases with and without
adverse reactions as regards DM being the most frequent co-
morbidity affected about one third of cases while other co-
morbidities were rare. As a result all patients shared 4 drugs
in this study (Oﬂoxacin, Ethionamide, PAS and Cycloserine),
Comparisons were done using the Chi square test between cases
with and without adverse reactions as regards the rest of the
anti-tuberculosis drugs (Kanamycin, Amikacin, Ethambutol,Table 2 Anti-tuberculosis drugs used by the studied cases.
Drug N %
Oﬂoxacin 138 100.0
Ethionamide 137 99.3
PAS 137 99.3
Cycloserine 136 98.6
Kanamycin 73 52.9
Amikacin 42 30.4
Ethambutol 25 18.1
Capreomycin 18 13.0
Streptomycin 5 3.6
Pyrazinamide 3 2.2
Anti-tuberculosis drugs used by the studied cases; data are pre-
sented as frequency and percentage.Capreomycin, Streptomycin, and Pyrazinamide). There was
no signiﬁcant relation between smoking, DM and used antitu-
berculosis drugs with ototoxicity, hypokalemia, hepatotoxicity,
hypothyroidism, gastrointestinal manifestation (including
IBS), skin manifestation (p> 0.05); while there was a signiﬁ-
cant relation between smoking and peripheral neuropathy
(p= 0.005).
Discussion
This retrospective study was to assess the adverse reactions
among 138 patients treated for MDR-TB in the period from
1st of July 2006 till 1st of January 2009 at MDR-TB depart-
ment in the Abbassia Chest Hospital. Results of this study ver-
iﬁed that the number of MDR-TB patients increased annually
which was 27 in 2006, 42 in 2007 and reached 69 in 2008 which
Figure 3 Serum creatinine among the studied cases using paired
t-test test, difference from each month to 1st month. There were
signiﬁcant elevations of creatinine beginning from 3rd month of
treatment (p< 0.05).
Figure 4 Serum Potassium level among the studied cases. There
were no signiﬁcant changes in serum Potassium levels among the
studied cases all through the follow up period using paired t-test
test, difference from each month to the 1st month.
Table 4 Overall severities of adverse reactions among the
studied cases.
Severity No. %
None 5 3.6
Does not aﬀect daily activity 120 87.0
Limits daily activity 10 7.2
Life threatening conditions 3 2.2
Severity grade of adverse reactions are represented as frequency (N)
and percentage (%).
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health problem in Egypt, which agrees with Prasad who stated
that multi drug resistant tuberculosis (MDR-TB) is a growingFigure 5 Adverse reactionshazard to human health world wide [10]. In our study, the
mean age was 37.6 years as in agreement with another previous
Egyptian study [11]. This age represents the period of physical,
mental, and occupational stress. The results also coincide with
those founded in Russia, South Africa and Iran [12–14]. As
regards sex distribution, there was male predominance (99
cases) representing (71.7%) which agrees with some studies
[11–14] but disagrees with others who stated that the females
were more because they were more likely to be young with
HIV positive [13]. In 2013; the male: female ratio of notiﬁed
cases across all age groups was 1.6 globally [15]. This has been
explained both by socio- cultural factors, thus run a greater
risk of exposure to contagious cases [16], and by immunolog-
ical differences between men and women that make males
more susceptible than females to some infections [17]. As
regards special habits, the most frequent special habit in this
study was tobacco smoking that represented 27.5% of cases
(38 patients), followed by Alcohol intake that comes second
in 7 cases and represents 5.1% of the studied group and lastly
drug addiction by 4 patients which represents 2.9% only.
Many results of earlier studies are in agreement [11–19].
Thus smoking has been found to be associated with both risk
of relapse of TB and TB mortality, moreover Passive smoking
also increases the risk of TB [20]. The incidence of Overall co
morbidity represents 54.1% (61 cases) and the most common
co-morbidity was diabetes mellitus [34.8% of the studied
patients (48 cases)], followed by liver disease; represented by
3.6% of patients (5 cases) and lastly chronic pulmonary diseaseamong the studied cases.
662 M.A.T. El-Din et al.(COPD); represented by 2.9% of patients (4 cases). This was
contrary to other studies that reported that the most common
comorbidity in their study was HIV positive followed by
Diabetes and chronic hepatic and renal disease [18]. This
may be due to the higher prevalence of HIV in the United
Kingdom than in Egypt. In agreement with these results,
Sobhy et al. reported that the frequency of diabetes mellitus
was 15% of the studied patients (17 cases) compared to other
co-morbidities in MDR-TB patients [11]. Lower percentage of
diabetes mellitus was reported by Furin et al. who found
comorbid conditions at MDR-TB diagnosis included diabetes
(1.7%); HIV (1.7%) and alcoholism (3.3%) [21]. Another
study indicated that poorly controlled diabetes confers a 2.9-
fold increase in the risk of developing pulmonary tuberculosis;
the risk associated with well-controlled diabetes was minimal
[22]. The mechanism by which diabetes may be related in part
to altered cytokine expression [23]. The study provided data
that ‘‘Resistance in previously treated cases’’, previously known
as acquired or secondary resistance, was 95.7% (132 patients)
and ‘‘resistance in new cases’’, previously known as initial or
primary resistance, was 4.3% (6 patients only). This might
be due to genetic factors and/or factors related to inadherence
to chemotherapy or inappropriate regimens. These results
coincided with those reported by Elmahallawy and his cowork-
ers [24]. In the present study, cured patients were 122 cases
(88.4%), dead patients were 11 cases (8%), Lost to follow-up
was only one case (0.7%) and treatment completed were 4
cases (2.9%). These results do not match with those of
Isaakidis et al. who reported that (19.4%) were successfully
treated, 20.9% died, and defaulted was 13.4% [25]. This differ-
ence might be due to that Isaakidis et al. study enrolled 67
patients only. On the other hand, the results matched with
other studies [12,18,24]. As regards occurrence of adverse reac-
tions, this study shows that the overall prevalence of adverse
reactions is 96.4 which is much more than that of earlier stud-
ies [12,26]. The heterogeneity in the prevalence of adverse
events across various studies might be related to several possi-
ble factors such as: differences in deﬁnitions of adverse events
terminologies, patient-reported (subjective) or clinician-
validated (objective), [27]. There was insigniﬁcant difference
between males and females according to the frequency of drug
complications. The most common adverse reaction in this
study is gastrointestinal manifestations representing 58.7%,
followed by peripheral polyneuritis 51.4%, hypokalemia
25.4%, IBS 23,9%, Ototoxicity 18.8%, Hypothyroidism
9.4%, Skin manifestations 12.3%, 8.7%, Depression 3.6%
and nephrotoxicity 2.9%, coinciding with some of the studies
[11,24,28,29]. On the other hand these results do not coincide
with those of Jacobs and Ross who reported that adverse
events in descending order of frequency were hearing loss
and vestibular disturbance; peripheral neuropathy; gastroin-
testinal disturbances, arthralgia [13]. Comparison between
cases with and without gastrointestinal manifestation as
regards smoking, DM and used anti-tuberculosis drugs showed
that there was no signiﬁcant difference. Regarding
Hepatotoxicity, as adverse reaction, it represented 8.7% of
the studied group (12 patients) that started to appear in the
ﬁfth month after staring treatment. Higher percentage
(16.8%) had been reported by Shin et al. [12]. It is presumed
that it is a side effect of prothionamide, PAS, pyrazinamide
and quinolones, and the whole treatment was suspended till
the recovery and resolution of symptoms. An alarming ﬁndingof our study was the highly frequent occurrence of peripheral
neuropathy exceeding half the patients enrolled in the study
(71 patients) representing 51.4% that started to appear early
in the 3rd month requiring awareness and the timely attention
of the physician because Baghaei et al. founded a highly signif-
icant association between neurologic side effects and mortality
[14]. Besides it had signiﬁcant relation with smoking. During
monitoring laboratory investigation for electrolyte abnormali-
ties, 25.4 had hypokalemia (serum potassium less than
3.5 mEq/L). Low serum potassium level started to be detected
ranging from the 2nd month to the 5th month with average at
the 3rd month of starting treatment which is likely multifacto-
rial. This was due to association with a number of chronic dis-
eases, such as tuberculosis, malnutrition, alcoholism, and
diabetes mellitus. In addition, diarrhea and vomiting caused
by antituberculous agents can contribute to GI electrolyte loss
found with GI manifestations that were the most common
adverse reactions. there was no signiﬁcant difference between
cases with and without hypokalemia as regards prescribed
anti-tuberculosis drugs as this may be because the patients
received another drugs rather than aminoglycosides that can
cause hypokalemia, that does not affect daily activities
{(31/35), 88.6%} and one patient only suffered from severe
hypokalemia and was treated by potassium supplementation
only. Ototoxicity, as an adverse reaction to MDR-TB treat-
ment, in our study represented 18.8% in the studied group
(26 cases). In comparison between cases with and without oto-
toxicity as regards smoking, DM and used anti-tuberculosis
drugs, we found that there was no signiﬁcant difference.
Also, there was no signiﬁcant relation between ototoxicity
and used antituberculosis drugs. These results do not coincide
with those of Kennedy et al. who found that eight patients
(61.5%) developed ototoxicity from long-term aminoglycoside
use [30], which matched with other studies [12,31]. In this
study, nephrotoxicity frequency was 2.9% (4 patients) due to
amino glycosides and started to appear in the 4th month after
staring treatment. 3 patients experienced mild adverse reac-
tions that did not need stoppage of any drug. Higher results
were reported by Shin et al. (9.8%) [12]. Lower results were
founded by Nathanson et al. (1.2%) [32]. Psychiatric disorders
were minimal (deﬁned as presence of depression, anxiety,
nightmares or psychotic symptoms) and were also observed
in 5 patients (3.6%) in the form of depression. One patient
only suffered from moderate to severe depression and we initi-
ated antidepressant and anti-psychotic therapy. Similar results
were observed by Sagwa et al. (3.5%) [26]. Higher results had
been reported by Nathanson et al. (3.4%) [32], and were sim-
ilar to other studies [12,13]. Psychiatric disorders may be
explained partly due to loss of conﬁdence in the health services,
effectiveness of treatment, long duration of the course and may
be a direct effect of the received drugs. Psychosis has been
reported as a side effect of CS and ﬂuoroquinolones, and
depression, while it has been associated with other drugs in
the MDR-TB treatment regimen, and is primarily associated
with CS [33]. Concerning hypothyroidism it developed in 13
cases representing 9.4% of studied patients. It appeared in
average after 6 months of starting treatment and 8 patients
of 13 required only prescription of thyroxin. Our results coin-
cided with Furin et al. (10%) and a more recent and larger
study, Bloss et al. (8%) [21,34]. As regards the mean interval
from the initiation of therapy to the occurrence of an adverse
effect among the studied cases, were during the ﬁrst 7 months
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with those who reported a shorter duration, early occurrence
of adverse effects may be due to the extended exposure to
aminoglycosides and capreomycin during or prior to MDR-
TB treatment [35]. On the other hand, these results are in
agreement with another, who reported that most adverse reac-
tions occurred during the ﬁrst 8 months of treatment [12].
In conclusion, the most common type of resistance was
acquired resistance because of lack of adherence to treatment
or inappropriate treatment, There was a relation between both
tobacco smoking and drug addiction, and MDR TB, The most
common co-morbidities associated with MDR TB were dia-
betes and chronic liver disease, Mild-to-Moderate adverse
events are common during MDR-TB treatment. The most
common side effect of anti TB drugs was GIT manifestations
and the least complication was dizziness. Adverse reactions
did not negatively impact treatment outcome among individu-
als who were adherent to treatment. To limit the resistance,
anti-tuberculosis medication especially INH and rifampicin,
they should not be prescribed for diseases other than tubercu-
losis and restricted in the private health sector. Continuous
medical education should be given for medical and para-
medical personnel and Health education for general
populations.
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